145.26
前日終値:
$146.93
開ける:
$146.27
24時間の取引高:
678.59K
Relative Volume:
0.69
時価総額:
$14.48B
収益:
$2.41B
当期純損益:
$305.80M
株価収益率:
49.24
EPS:
2.95
ネットキャッシュフロー:
$492.20M
1週間 パフォーマンス:
+0.18%
1か月 パフォーマンス:
-4.17%
6か月 パフォーマンス:
+14.64%
1年 パフォーマンス:
+4.48%
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
名前
Neurocrine Biosciences Inc
セクター
電話
(858) 617-7600
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
NBIX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
NBIX
Neurocrine Biosciences Inc
|
145.26 | 14.65B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
126.23 | 55.30B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.65 | 49.22B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.13 | 44.97B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.89 | 36.41B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
507.16 | 22.16B | 3.08B | 1.24B | 1.07B | 25.61 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-21 | 開始されました | Citigroup | Buy |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-07-10 | 開始されました | Goldman | Buy |
| 2025-04-15 | アップグレード | Needham | Hold → Buy |
| 2025-04-14 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 開始されました | Deutsche Bank | Hold |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-08-29 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 再開されました | Citigroup | Neutral |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 繰り返されました | Mizuho | Neutral |
| 2023-07-24 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | アップグレード | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-03-30 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-02-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 開始されました | UBS | Buy |
| 2022-09-26 | 開始されました | Wells Fargo | Equal Weight |
| 2022-06-06 | 再開されました | Jefferies | Buy |
| 2022-03-03 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | アップグレード | Goldman | Neutral → Buy |
| 2022-01-18 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 開始されました | BMO Capital Markets | Underperform |
| 2021-11-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-10-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 再開されました | Needham | Hold |
| 2021-08-06 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 再開されました | Goldman | Neutral |
| 2021-05-06 | アップグレード | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 開始されました | Raymond James | Outperform |
| 2020-09-30 | 開始されました | The Benchmark Company | Hold |
| 2020-08-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-06-29 | ダウングレード | Goldman | Buy → Neutral |
| 2020-06-09 | 開始されました | Wedbush | Outperform |
| 2020-03-06 | 開始されました | Citigroup | Buy |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-24 | 開始されました | William Blair | Outperform |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2020-02-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-12-13 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-07-16 | 開始されました | Oppenheimer | Outperform |
| 2019-06-05 | 開始されました | Guggenheim | Neutral |
| 2019-05-21 | 開始されました | Credit Suisse | Outperform |
| 2019-04-22 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-02-06 | 繰り返されました | BofA/Merrill | Buy |
| 2019-01-23 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 開始されました | Goldman | Buy |
| 2018-11-21 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Neurocrine Biosciences Inc (NBIX) 最新ニュース
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Rice Hall James & Associates LLC - MarketBeat
Neurocrine Biosciences director sells shares worth $269,167 - MSN
Swedbank AB Has $76.83 Million Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NBIX) Stock News: Brighton Jones Raises Stake to $1.43M - Eudaimonia and Co
Brighton Jones LLC Has $1.43 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Earnings Notes - Trefis
AbbVie, Neurocrine End One Orilissa Patent Case Against Hetero - Bloomberg Law News
Voya Investment Management LLC Cuts Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
What's Going On With Neurocrine Biosciences Stock Tuesday?Neurocrine Biosciences (NASDAQ:NBIX) - Benzinga
Neurocrine’s valbenazine misses Phase III goals in DCP - The Pharma Letter
Neurocrine Biosciences (NBIX): Assessing Valuation After New Phase 2 Bipolar I Mania Trial Launch - Sahm
Neurocrine : Phase 3 Study Of Valbenazine In Dyskinetic Cerebral Palsy Fails To Meet Main Goal - Nasdaq
Neurocrine's Ingrezza fails in phase 3 trial for dyskinetic cerebral palsy (NBIX:NASDAQ) - Seeking Alpha
Neurocrine's movement disorder treatment fails late-stage trial - marketscreener.com
Neurocrine's Phase 3 Trial of Valbenazine in Dyskinetic Cerebral Palsy Fails to Meet Primary, Key Secondary Endpoints - marketscreener.com
Neurocrine’s phase 3 trial for cerebral palsy drug fails to meet endpoints - Investing.com
Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy - PR Newswire
Assenagon Asset Management S.A. Sells 13,280 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine’s Growth Story Runs Through INGREZZA And The Pipeline - Finimize
HC Wainwright & Co. maintains Neurocrine Biosciences (NBIX) buy recommendation - MSN
What hedge fund activity signals for Neurocrine Biosciences Inc. stock2025 Valuation Update & Weekly Sector Rotation Insights - Bölüm Sonu Canavarı
How Neurocrine Biosciences Inc. stock valuations compare to rivals2025 Volatility Report & Fast Gaining Stock Reports - Улправда
Merger Talk: Can Neurocrine Biosciences Inc. stock beat analyst upgrades2025 EndofYear Setup & Risk Managed Investment Entry Signals - moha.gov.vn
Is Neurocrine Biosciences (NBIX) Quietly Recasting Its Long-Term Story Around Metabolic Disease Innovation? - simplywall.st
How Neurocrine Biosciences Inc. (NB3) stock reacts to monetary easing2025 Earnings Surprises & Low Risk Entry Point Tips - ulpravda.ru
How Neurocrine Biosciences Inc. stock performs in weak economyQuarterly Earnings Summary & Weekly Hot Stock Watchlists - Улправда
Nxera Knocked Back As Boehringer Bows Out Of Schizophrenia Pact - Citeline News & Insights
Is Neurocrine Biosciences Inc. (NB3) stock a momentum leaderPortfolio Gains Summary & Technical Pattern Recognition Alerts - DonanımHaber
Why Neurocrine Biosciences Inc. stock is favored by pension fundsQuarterly Market Summary & Growth Focused Entry Point Reports - DonanımHaber
Neurocrine Bio. stock price target raised to $198 by H.C. Wainwright - Investing.com Canada
Published on: 2025-12-18 16:31:37 - Улправда
RBC Capital Keeps Their Buy Rating on Neurocrine (NBIX) - The Globe and Mail
HC Wainwright & Co. Maintains Neurocrine Biosciences (NBIX) Buy Recommendation - Nasdaq
Neurocrine Biosciences (NASDAQ:NBIX) Director Leslie Norwalk Sells 1,190 Shares - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Director Leslie Norwalk Sells 5,000 Shares - MarketBeat
Neurocrine Biosciences Director Sells Shares - TradingView — Track All Markets
Neurocrine Bio. stock price target reiterated at $200 by TD Cowen - Investing.com Canada
Key facts: HC Wainwright maintains 'Buy' on Neurocrine; price target rises - TradingView — Track All Markets
Neurocrine Bio. stock holds Buy rating at Jefferies after R&D Day - Investing.com Canada
Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Neurocrine Bio. stock rating reiterated at Outperform by RBC Capital - Investing.com Canada
Texas Permanent School Fund Corp Sells 11,976 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine showcases R&D across neuroscience and endocrinology - The Pharma Letter
Neurocrine Bio. stock holds steady as BMO reiterates $147 price target - Investing.com UK
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology - PR Newswire
What analysts say about Neurocrine Biosciences Inc stockMomentum Trading Signals & Free Daily Top Stock Picks for All Investors - earlytimes.in
Dir Norwalk Files To Sell 11,250 Of Neurocrine Biosciences Inc [NBIX] - TradingView — Track All Markets
Hudson Bay Capital Management LP Has $9.75 Million Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NBIX): Revisiting Valuation After a Year of Double-Digit Shareholder Returns - simplywall.st
Thrivent Financial for Lutherans Cuts Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat
Neurocrine Biosciences Inc (NBIX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):